B of A Securities Maintains Buy on Travere Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Greg Harrison maintains a Buy rating on Travere Therapeutics and raises the price target from $18 to $20.
October 09, 2024 | 5:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
B of A Securities has reaffirmed its Buy rating on Travere Therapeutics and increased the price target from $18 to $20, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and an increase in the price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100